首页 | 本学科首页   官方微博 | 高级检索  
     

表没食子儿茶素没食子酸酯对小鼠非酒精性脂肪肝的干预作用
引用本文:沈晶,舒恒,石孟琼,张媛媛,朱丽金,雷乾坤,张继红,贺海波,邹坤.表没食子儿茶素没食子酸酯对小鼠非酒精性脂肪肝的干预作用[J].现代食品科技,2021,37(4):33-43.
作者姓名:沈晶  舒恒  石孟琼  张媛媛  朱丽金  雷乾坤  张继红  贺海波  邹坤
作者单位:三峡大学医学院,湖北宜昌 443002;三峡大学天然产物研究与利用湖北省重点实验室,湖北宜昌 443002;三峡大学中医临床医学院,湖北宜昌 443001;药食同源大健康产品开发利用宜昌市重点实验室,湖北宜昌 443002;三峡大学天然产物研究与利用湖北省重点实验室,湖北宜昌 443002;药食同源大健康产品开发利用宜昌市重点实验室,湖北宜昌 443002
基金项目:宜昌市科学技术局资助项目(A18-302-a2);三峡大学硕士学位论文培优基金资助项目(2020SSPY114;2019SSPY159)
摘    要:本文研究了表没食子儿茶素没食子酸酯(EGCG)对小鼠非酒精性脂肪性肝病(NAFLD)的干预作用。应用高脂饲料喂养Apo E-/-小鼠建立NAFLD小鼠模型,研究EGCG对NAFLD小鼠血液和肝组织中糖脂代谢、脂肪酸氧化、氧化应激水平、肝组织结构以及AMPK/SIRT1/SREBP-1c/PPARγ信号通路相关基因表达的影响。结果表明EGCG治疗后肝组织病理学变化明显改善,小鼠体质量、肝质量、肝质量指数较模型组显著降低至110.98%、115.01%,115.64%、136.48%和104.20%、118.70%(p<0.01);血液和肝组织中糖脂代谢、脂肪酸氧化、氧化应激水平改善幅度在11.85%~86.06%之间,与模型组比较具有显著性差异(p<0.05或p<0.01);升高肝组织中AMPKα、SIRT1 mRNA及p-AMPKα、SIRT1蛋白表达幅度在13.21%~75.82%之间,降低肝组织FASN、ACC-1、SREBP-1c、SCD-1、PPARγm RNA和FASN、p-ACC-1、p-SREBP-1c、SCD-1、PPARγ蛋白表达幅度在19.59%~92.07%之间,改善p-AMPKα/AMPKα、p-ACC-1/ACC-1和p-SREBP-1c/SREBP-1c比率在39.20%~93.07%之间,与模型组比较具有显著性差异(p<0.05或p<0.01)。本研究表明EGCG可通过调控AMPK/SIRT1/SREBP-1c/PPARγ信号通路相关基因的表达来改善NAFLD小鼠糖脂代谢、脂肪酸氧化和氧化应激状态。

关 键 词:没食子儿茶素没食子酸酯  非酒精性脂肪性肝病  AMPK/SIRT1/SREBP-1c/PPARγ信号通路
收稿时间:2020/9/10 0:00:00

Effects of Epigallocatechin-3-gallate on Nonalcoholic Fatty Liver Disease in Mice
SHEN Jing,SHU Heng,SHI Meng-qiong,ZHANG Yuan-yuan,ZHU Li-jin,LEI Qian-kun,ZHANG Ji-hong,HE Hai-bo,ZOU Kun.Effects of Epigallocatechin-3-gallate on Nonalcoholic Fatty Liver Disease in Mice[J].Modern Food Science & Technology,2021,37(4):33-43.
Authors:SHEN Jing  SHU Heng  SHI Meng-qiong  ZHANG Yuan-yuan  ZHU Li-jin  LEI Qian-kun  ZHANG Ji-hong  HE Hai-bo  ZOU Kun
Affiliation:(1.Medical Science College, China Three Gorges University, Yichang 443002, China);(2.Hubei Key Laboratory of Natural Products Research and Development, China Three Gorges University, Yichang 443002, China);(2.Hubei Key Laboratory of Natural Products Research and Development, China Three Gorges University, Yichang 443002, China) (3.Chinese Medicine Clinical Medical College, China Three Gorges University, Yichang 443001, China);(2.Hubei Key Laboratory of Natural Products Research and Development, China Three Gorges University, Yichang 443002, China)(4.Yichang Key Laboratory of Development and Utilization Large Health Products with Medicine Food Homology, Yichang 443002, China)
Abstract:The protective effects of epigallocatechin gallate(EGCG)on nonalcoholic fatty liver disease(NAFLD)in mice were investigated.The NAFLD Apo E-/-mice model was established by feeding high fat food.Then,the effects of EGCG on glucose and lipid metabolism,fatty acid oxidation,oxidative stress level,liver tissue structure and the gene expressions of AMPK/SIRT1/SREBP-1 c/PPARγsignaling pathway in NAFLD mice were analyzed.The results indicated that after EGCG treatment,the pathological changes of liver tissue were evidently ameliorated;compared with the model group,the body weight,liver mass and liver mass index of mice were significantly reduced to 110.98%,115.01%,115.64%,136.48%and 104.20%,118.70%respectively(p<0.01,respectively).The levels of glucose and lipid metabolism,fatty acid oxidation and oxidative stress in blood and liver tissues were markedly improved by 11.85%~86.06%compared with model group(p<0.05 or p<0.01,respectively).Further study indicated that the AMPKα,SIRT1 m RNA and p-AMPKα,SIRT1 protein expressions in liver tissue were obviously elevated by 13.21%~75.82%.In contrast,the FASN、ACC-1、SREBP-1 c、SCD-1、PPARγm RNA and FASN、p-ACC-1、p-SREBP-1 c、SCD-1、PPARγprotein expressions in liver tissue were dramatically reduced by 19.59%~92.07%,the p-AMPKα/AMPKα、p-ACC-1/ACC-1 and p-SREBP-1 c/SREBP-1 c ratios significantly ameliorated by 39.20%~93.07%compared with model group(p<0.05 or p<0.01,respectively).The results demonstrated that EGCG could ameliorate glucose and lipid metabolism,fatty acid oxidation and oxidative stress in NAFLD mice by regulating there lated gene expressions of AMPK/SIRT1/SREBP-1 c/PPARγsignaling pathway.
Keywords:epigallocatechin-3-gallate(EGCG)  nonalcoholic fatty liver disease(NAFLD)  AMPK/SIRT1/SREBP-1c/PPARγsignaling pathway
本文献已被 CNKI 维普 万方数据 等数据库收录!
点击此处可从《现代食品科技》浏览原始摘要信息
点击此处可从《现代食品科技》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号